
Natus Medical Incorporated NTUS
Quarterly report 2022-Q1
added 12-23-2023
Natus Medical Incorporated General and Administrative Expenses 2011-2026 | NTUS
General and Administrative Expenses — these are a part of a company's operating expenses that are not directly related to the production of goods or the provision of services but are necessary for the overall functioning of the business.What these expenses include
- Salaries of administrative staff (executives, HR, accountants, legal personnel)
- Office rent and utilities
- Office equipment and IT infrastructure
- Professional services (auditors, lawyers, consultants)
- Insurance
- General administrative travel and representation expenses
- Cost control
A high level of such expenses may indicate inefficient management or an overly complex structure - Profitability
Reducing administrative expenses while maintaining stable revenue increases operating profit - Comparative analysis
Investors can compare this metric as a percentage of revenue among companies in the same industry - Business flexibility
Companies with a flexible and controlled expense structure are more resilient to revenue declines
Annual General and Administrative Expenses Natus Medical Incorporated
| 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|
| 52.8 M | 49.1 M | 59.6 M | 68.7 M | 74.4 M | 50.9 M | 46.4 M | 49.3 M | 48.5 M | 51 M | 32.9 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 74.4 M | 32.9 M | 53 M |
Quarterly General and Administrative Expenses Natus Medical Incorporated
| 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | 12.8 M | - | 12.9 M | 12.6 M | 14.9 M | - | 12.4 M | 11.2 M | 13.2 M | - | 15.4 M | 12.7 M | 16.3 M | - | 15.8 M | 23.7 M | 17.4 M | - | 17.3 M | 24.2 M | 16 M | - | 12.8 M | 11.9 M | 12.5 M | - | 10 M | 11.7 M | 11.6 M | - | 12.7 M | 10.2 M | 11.7 M | - | 14.3 M | 11.8 M | 14 M | - | 18.8 M | 10.9 M | 9.5 M | - | 7.81 M | 7.99 M | 9.03 M |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 24.2 M | 7.81 M | 13.5 M |
General and Administrative Expenses of other stocks in the Medical devices industry
| Issuer | General and Administrative Expenses | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
Aethlon Medical
AEMD
|
3.24 M | $ 2.19 | 3.79 % | $ 3.42 M | ||
|
AdaptHealth Corp.
AHCO
|
382 M | $ 10.66 | 2.3 % | $ 1.44 B | ||
|
Allied Healthcare Products
AHPI
|
7.11 M | - | 3.58 % | $ 2.21 M | ||
|
GenMark Diagnostics, Inc.
GNMK
|
25.6 M | - | - | $ 1.77 B | ||
|
Acutus Medical
AFIB
|
14.1 M | - | -26.83 % | $ 2.62 M | ||
|
Butterfly Network
BFLY
|
39.8 M | $ 4.08 | 4.09 % | $ 864 M | ||
|
Alphatec Holdings
ATEC
|
499 M | $ 12.79 | 1.51 % | $ 1.92 B | ||
|
Obalon Therapeutics, Inc.
OBLN
|
8.78 M | - | -5.86 % | $ 30.6 M | ||
|
Aziyo Biologics
AZYO
|
15.1 M | - | 1.37 % | $ 20.5 M | ||
|
Avinger
AVGR
|
14.1 M | - | -20.74 % | $ 369 K | ||
|
BIOLASE
BIOL
|
10.2 M | - | -13.19 % | $ 166 K | ||
|
Cognyte Software Ltd.
CGNT
|
163 M | $ 8.36 | -0.24 % | $ 600 M | ||
|
Boston Scientific Corporation
BSX
|
6.89 B | $ 71.81 | 2.94 % | $ 106 B | ||
|
CONMED Corporation
CNMD
|
132 M | $ 36.75 | -1.76 % | $ 1.14 B | ||
|
Conformis
CFMS
|
28.8 M | - | - | $ 16.4 M | ||
|
Cytosorbents Corporation
CTSO
|
35 M | $ 0.69 | 6.83 % | $ 37.6 M | ||
|
Apollo Endosurgery
APEN
|
20.6 M | - | - | $ 475 M | ||
|
EDAP TMS S.A.
EDAP
|
5.9 M | $ 4.12 | 3.91 % | $ 154 M | ||
|
Cutera
CUTR
|
63.3 M | - | -10.19 % | $ 1.99 M | ||
|
Establishment Labs Holdings
ESTA
|
165 M | $ 64.8 | 2.08 % | $ 1.92 B | ||
|
CryoLife, Inc.
CRY
|
141 M | - | -4.14 % | $ 702 M | ||
|
Dynatronics Corporation
DYNT
|
8.46 M | - | 14.99 % | $ 929 K | ||
|
ClearPoint Neuro
CLPT
|
12 M | $ 11.12 | 0.82 % | $ 301 M | ||
|
Axonics Modulation Technologies
AXNX
|
40.2 M | - | - | $ 3.31 B | ||
|
Soliton, Inc.
SOLY
|
8.46 M | - | -1.42 % | $ 435 M | ||
|
Hancock Jaffe Laboratories, Inc.
HJLI
|
4.88 K | - | -1.98 % | $ 98.3 M | ||
|
Itamar Medical Ltd.
ITMR
|
8.5 M | - | 0.03 % | $ 1.58 B | ||
|
Misonix, Inc.
MSON
|
18 M | - | - | $ 462 M | ||
|
Neovasc
NVCN
|
14.7 M | - | - | $ 111 M | ||
|
FONAR Corporation
FONR
|
23.5 M | $ 18.43 | 0.08 % | $ 121 M | ||
|
Helius Medical Technologies
HSDT
|
9.27 M | $ 2.22 | 1.37 % | $ 1.35 M | ||
|
GBS
GBS
|
8.88 M | - | -0.57 % | $ 7.12 M | ||
|
InMode Ltd.
INMD
|
8.41 M | $ 13.58 | 1.08 % | $ 878 M | ||
|
Intersect ENT, Inc.
XENT
|
98.6 M | - | - | $ 955 M | ||
|
IRIDEX Corporation
IRIX
|
8.75 M | $ 1.31 | -1.5 % | $ 21.1 M | ||
|
Abbott Laboratories
ABT
|
12.3 B | $ 111.67 | 1.56 % | $ 194 B | ||
|
Delcath Systems
DCTH
|
43.5 M | $ 9.84 | 0.31 % | $ 352 M | ||
|
Bio-Rad Laboratories
BIO
|
814 M | $ 268.33 | 2.72 % | $ 7.57 B | ||
|
Integra LifeSciences Holdings Corporation
IART
|
717 M | $ 9.19 | 2.0 % | $ 708 M | ||
|
LivaNova PLC
LIVN
|
549 M | $ 62.26 | 1.34 % | $ 3.4 B | ||
|
AxoGen
AXGN
|
44.6 M | $ 32.83 | -0.03 % | $ 1.51 B | ||
|
Align Technology
ALGN
|
1.76 B | $ 176.49 | 4.15 % | $ 13.2 B | ||
|
Bruker Corporation
BRKR
|
894 M | $ 33.53 | 2.35 % | $ 5 K | ||
|
BioSig Technologies
BSGM
|
11.6 M | - | 37.08 % | $ 85.7 M | ||
|
Apyx Medical Corporation
APYX
|
15.8 M | $ 3.77 | 2.72 % | $ 155 M | ||
|
OrthoPediatrics Corp.
KIDS
|
120 M | $ 17.17 | 0.35 % | $ 403 M | ||
|
Integer Holdings Corporation
ITGR
|
212 M | $ 86.71 | 3.14 % | $ 3.01 B | ||
|
MiMedx Group
MDXG
|
56.5 M | $ 4.46 | 1.02 % | $ 659 M |